Accepting applications until August 1
Accepting applications until August 1
Yek-Ching Kong, Jean Niyigaba, Phuong Bich Tran, et al.
Cancer is among the most important causes of premature deaths globally. We estimated the value of paid and unpaid productivity losses due to premature mortality in 2022 from all cancers worldwide.Years of productive life lost were... Read More
Agnes Brandtmüller, Anne Meiwald, Edward Oliver, et al. J Cancer Policy. 2024 Dec:42:100499
Cancer caused an estimated 2.2 million deaths across Europe in 2020. This analysis estimated the cost of lost productivity due to premature deaths associated with lung, breast and melanoma cancer and investigated the temporal tren... Read More
Zachary J Ward, Fabio Ynoe Moraes, Andrew M Scott, et al. Lancet Oncol. 2026 May;27(5):560-568
Cancer survival has improved in many countries in recent decades, but large disparities remain globally. Understanding the effects of workforce shortages, stage at diagnosis, and broader health system barriers on poor survival is... Read More
GBD 2023 Cancer Collaborators. Lancet. 2025 Oct 11;406(10512):1565-1586
In 2023, excluding non-melanoma skin cancers, there were 18·5 million incident cases of cancer and 10·4 million deaths, contributing to 271 million DALYs globally. Of these, 57·9% of incident cases and 65·8% of cancer deaths occur... Read More
Sapna P Patel, Megan Othus, Yuanbin Chen et al. N Engl J Med. 2023 Mar 2;388(9):813-823
In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adju... Read More
Christian U Blank, Minke W Lucas, Richard A Scolyer et al. N Engl J Med. 2024 Nov 7;391(18):1696-1708
In this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma to two cycles of neoadjuvant ipilimumab plus nivolumab followed by surgery or surgery followed by 12 cycles of adjuvant nivolumab... Read More
Oliver Langselius , Harriet Rumgay, Esther de Vries, David C Whiteman et al. Int J Cancer. 2025 Sep 15;157(6):1110-1119
Cutaneous melanoma (CM) accounted for around 331,700 cancer cases globally in 2022. Ultraviolet radiation (UVR) is a major CM risk factor. In this study, we update and improve global estimates of UVR-attributable CM cases. An esti... Read More
Giuseppe De Pinto, Silvia Mignozzi, Carlo La Vecchia, et al. Melanoma Res. 2024 Jun 1;34(3):265-275
Mortality from cutaneous malignant melanoma (CMM) increased in the past, but trends have been favorable in more recent years in many high-income countries. However, incidence has been increasing in several countries. Mortality fro... Read More
S. Ogino and T. Ugai. Annals of Oncol;.35(12) 1071-1073. 2024
The incidence of early-onset cancer (EOC) diagnosed in individuals under the age of 50 has been increasing worldwide, which may be just the tip of the iceberg of larger emerging issues, including the rise of various chronic diseas... Read More
Marta Ortega Ortega, Paul Hanly, Alison Pearce, et al. Applied Health Economics and Health Policy (2023) 21:877–889
Between 2018 and 2040, cancer is expected to cause around eight million premature deaths (58% male). The cumulative projected productivity costs in this respect are €1.3 trillion, representing an annual average of €58.7 billion, o... Read More
Danielle Brabender, Emily Siegel, Julie O. Culver, et al. Ann Surg Oncol (2025) 32:9041–9049
Only a subset of individuals meeting National Comprehensive Cancer Network (NCCN) guidelines for genetic screening of hereditary cancers are being offered testing. A total of 14,192 women were screened, with 3224 (23%) meeting NCC... Read More
Douglas B. Johnson, Amin H. Nassar, Ayesha Aijaz,et al. Nat Rev Clin Oncol 2026 Feb 18.
Anti-PD-L1 antibodies have transformed cancer treatment and are increasingly being used in patients with early-stage malignancies including in the adjuvant and neoadjuvant settings. In this Review, we explore the optimal use of an... Read More